TG Therapeutics, Inc.
TGTX
Rank in Stocks
#2355
Based in New York City and established in 1993, TG Therapeutics, Inc. is a... Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Share Price
$54.70
Last synced: 2026-10-20
Market Cap
$8.37B
Change (1 day)
2.63%
Change (1 year)
55.31%
Country
US
Trade TG Therapeutics, Inc. (TGTX)
Category
Healthcare
P/E ratio for TG Therapeutics, Inc. (TGTX)
P/E ratio as of October 2026 TTM: 17.86
According to TG Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 17.86. At the end of 2023 the company had a P/E ratio of 191.33.
P/E ratio history for TG Therapeutics, Inc. from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 17.86 | -90.45% |
| 2024 | 187.06 | -2.23% |
| 2023 | 191.33 | -2,468.94% |
| 2022 | -8.08 | 11.91% |
| 2021 | -7.22 | -66.39% |
| 2020 | -21.47 | 278.47% |
| 2019 | -5.67 | 218.13% |
| 2018 | -1.78 | -58.48% |
| 2017 | -4.30 | 47.42% |
| 2016 | -2.91 | -66.31% |
| 2015 | -8.65 | -10.58% |
| 2014 | -9.67 | 99.88% |
| 2013 | -4.84 | 83.25% |
| 2012 | -2.64 | 3.52% |
| 2011 | -2.55 | -179.01% |
| 2010 | 3.23 | -259.65% |
| 2009 | -2.02 | 52.83% |
| 2008 | -1.32 | 192.68% |
| 2007 | -0.45 | -8.83% |
| 2006 | -0.50 | 172.53% |
| 2005 | -0.18 | -50.21% |
| 2004 | -0.37 | 21.63% |
| 2003 | -0.30 | -53.56% |
| 2002 | -0.65 | 339.61% |
| 2001 | -0.15 | 771.01% |
| 2000 | -0.02 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | 61.19% |
US
|
|
| -28.36 | -258.82% |
US
|
|
| -24.57 | -237.58% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 69.86% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.